Company: ARMP
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001104659-25-040273
Chunk: 60

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 60
---
’s immediate family members and any entity owned or controlled by any such persons. Under the policy, where a transaction has been identified as a related-person transaction, management must present information regarding the proposed related-person transaction to our Audit Committee (or, where review by our Audit Committee would be inappropriate, to another independent body of our Board of Directors) for approval. The presentation must include a description of, among other things, the material facts, the direct and indirect interests of the related persons, the benefits of the transaction to us and whether any alternative sources for comparable services or products are available. To identify related-person transactions in advance, we rely on information supplied by our executive officers, directors, director nominees and certain significant shareholders. In considering related-person transactions, our Audit Committee or other independent body of our Board of Directors takes into account the relevant available facts and circumstances including, but not limited to: • the risks, costs and benefits to us; • the impact on a director’s independence in the event the related person is a director, immediate family member of a director or an entity with which a director is affiliated; • the terms of the transaction; and • the terms available to or from, as the case may be, unrelated third parties. In the event a director has an interest in the proposed transaction, the director must recuse himself or herself from the deliberation and approval. Certain Related-Person Transactions Described below are any transactions occurring since January 1, 2024, and any currently proposed transactions, to which C3J or Armata was a party and in which: • The amounts involved exceeded or will exceed the lesser of (i) $120,000 and (ii) 1% of the average of the respective company’s total assets at year-end for the last two completed fiscal years; and • A director, director nominee, executive officer, holder of more than 5% of the outstanding capital stock of the respective company, or any member of such person’s immediate family had or will have a direct or indirect material interest. Financing Transactions 2025 Credit Agreement On March 12, 2025, the Company entered into a credit and security agreement (the “ 2025 Credit Agreement ”) for a loan in an aggregate amount of $10.0 million (the “ 2025 Loan ”) with Innoviva Strategic Opportunities LLC, a wholly owned subsidiary of Innoviva, Inc. (NASDAQ: INVA), our principal stockholder and a related party (collectively, “ Innoviva ”). The 202